Nanobiotix is a late-stage clinical biotech company, founded in 2003, developing physics-based nanotherapeutics for cancer, led by the radioenhancer NBTXR3.
Nanobiotix is a late-stage clinical biotechnology company founded in 2003 that discovers, develops, manufactures and commercialises physics-based nanotherapeutics for cancer and other challenging diseases. The company's approach applies physical principles rather than conventional biochemical mechanisms to alter the behaviour of tumour cells, and it has spent more than two decades working in this field from a base in France, with a stated focus on patients worldwide.
Its lead programme, NBTXR3, is a potential first-in-class radioenhancer. The product is designed to increase the dose of radiotherapy absorbed and deposited inside tumour cells without raising the dose delivered to surrounding healthy tissue. In addition to destroying the target tumour, it is intended to prime an immune response against metastatic tumours, and its therapeutic applications span a range of solid tumours. NBTXR3 is in late-stage clinical development.
The work sits at the intersection of several technical fields: nanomedicine, radiation oncology, immuno-oncology and tumour-targeted drug development. Combining physics-based nanotechnology with radiotherapy and immunotherapy implies disciplines spanning nanoparticle formulation, clinical oncology, radiation physics and translational research. The company describes its culture as rooted in a French legacy of scientific breakthroughs, with an emphasis on exploration beyond existing scientific solutions.
Industry verticals include biotechnology, drug development, oncology and radiation oncology.
